Moreover, incorporating biomarkers like PD-L1 expression, tumor-infiltrating lymphocytes (TILs), and the Ki67 index into clinical decision-making may help identify patients who are more likely to benefit from immunotherapy and combination regimens [16]. This evidence concerns the gene MKI67 and neoplasm.